Search Results
Your search for ,loW matches 7101 pages
Showing 951 - 1000ShortHER Update: 10-Year Survival Outcomes With 9 Weeks vs 1 Year of Adjuvant Trastuzumab in HER2-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by PierFranco Conte, MD, PhD, and colleagues, the final analysis of the Italian phase III noninferiority ShortHER trial showed little difference in 10-year disease-free survival and overall survival with 9 weeks vs 1 year of adjuvant trastuzumab in...
Liquid Biopsy May Help Identify Patients With NSCLC Who Could Benefit From Radiation Therapy
Liquid biopsy may help determine which patients with oligometastatic non–small cell lung cancer (NSCLC) with metastases may be most likely to benefit from targeted, high-dose radiation therapy rather than drug-based therapy, according to findings simultaneously published by Semenkovich et al in npj ...
Racial and Ethnic Minority Patients With Breast Cancer May Be Less Likely to Receive Palliative Care Than White Patients
Despite a steady increase in palliative care utilization from 2004 to 2020, racial and ethnic minority patients with metastatic breast cancer may be less likely to receive palliative care compared with non-Hispanic White patients with the disease, according to new findings presented by Freeman et...
Hypofractionated Radiotherapy May Reduce Burden of Head and Neck Cancer in Low- and Middle-Income Countries
Fewer and higher doses of radiation may be effective at treating patients with head and neck squamous cell carcinoma, according to new findings presented by Bentzen et al at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA 02). Background Head and neck squamous...
SBRT vs Standard Radiotherapy for Localized Prostate Cancer: 5-Year Analysis of PACE B
People with intermediate-risk, localized prostate cancer may be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggested. The findings, which...
FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types
On September 29, the U.S. Food and Drug Administration (FDA) granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test that may help detect hundreds of genetic variants associated with an elevated risk of developing certain cancers. The...
Long-Term Low-Grade Intestinal Inflammation May Be Prevalent Among Patients Who Have Undergone Radiotherapy
Researchers have found that low-grade intestinal inflammation may be a side effect of radiotherapy, according to a recent study published by Devarakonda et al in eBioMedicine. Background Radiotherapy is often necessary to cure cancer or slow down cancer development. Although today’s radiotherapies...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Ambulatory Thromboprophylaxis in Patients With Lung and Gastrointestinal Cancers
In an Australian phase III trial (TARGET-TP) reported in JAMA Oncology, Alexander et al found that ambulatory thromboprophylaxis reduced the risk of thromboembolic events in patients starting systemic therapy for lung or gastrointestinal cancer who were at elevated risk of thrombosis. Study ...
First-Line Dabrafenib/Trametinib in Pediatric BRAF V600–Mutated Low-Grade Glioma
In a phase II trial reported in The New England Journal of Medicine, Eric Bouffet, MD, and colleagues found that the combination of dabrafenib and trametinib produced a higher objective response rate vs standard chemotherapy in the first-line treatment of pediatric patients with low-grade glioma...
Gynecologic Cancer Misinformation May Be Widespread on TikTok
The majority of information related to gynecologic cancers on the social media platform TikTok may be misleading or inaccurate, according to a recent study published by Morton et al in Gynecologic Oncology. Background “The intent of this study was to understand the needs of patients that may go...
Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma
The management of sarcoma presents several challenges because of its rarity and diverse subtypes, making accurate diagnosis and specialized treatment crucial. A multidisciplinary approach involving various experts from different cancer specialties is the optimal strategy to improve survival and...
Surgical Oncologist Héber Salvador, MD, PhD, Offers an Inside Look at Cancer Care in Brazil, Complete With Its Diversity and Inequities
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, the Jerald L. & Carolynn J. Varner Professor of Surgical Oncology & Global Health at the University of Nebraska Medical Center, Omaha, spoke with Héber Salvador, MD, PhD,...
From Texas to Sweden, Medical Oncologist Gil Morgan, MD, Enjoys Connecting the Cancer Community
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Gil Morgan, MD, a clinical oncologist formerly at the Division of Medical and Radiation Oncology at Skåne University Hospital, Lund, Sweden and now full-time Director of the OncoAlert...
ASCO Releases Rapid Recommendation Update on Use of Olanzapine to Treat Cancer-Related Cachexia
ASCO recently released a new rapid recommendation update that addresses the use of olanzapine to treat cancer-related cachexia, a topic originally addressed in its 2020 guideline on the management of cancer cachexia in adults with advanced cancer.1,2 At that time, there was insufficient evidence to ...
More on Biliary Tract Cancer From ASCO 2023: Focus on Zanidatamab
The HER2-targeting bispecific antibody zanidatamab generated rapid and durable responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer previously treated with gemcitabine, investigators from the global phase IIb HERIZON-BTC-01 study reported at...
Understanding the Treatment of Waldenström’s Macroglobulinemia
Waldenström’s macroglobulinemia is a rare and incurable low-grade B-cell lymphoproliferative disease defined by specific genotypic subtypes that have implications for treatment response and long-term outcomes. Treatment—and there is no established standard—is mainly focused on controlling symptoms...
Colorectal Cancer Screening: Major Communication Gap in the Clinical Setting
According to the American Cancer Society, colorectal cancer is the second-leading cause of cancer-related death in the United States. In 2023, the disease is expected to cause an estimated 52,550 deaths. Studies show that receiving a clinician recommendation is the strongest and most consistent...
LungCAN Advocacy Program Nets 25% Increase in LCRP Funding
The Lung Cancer Action Network (LungCAN) advocacy program may have helped increase funding for the U.S. Department of Defense Congressionally Directed Medical Research Program/Lung Cancer Research Program (LCRP) by 25%, according to recent findings presented by Donaldson et al at the International...
ctDNA Identified in Breast Milk From Women With Breast Cancer
Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum may contain circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in ...
FDA Approves Momelotinib for Patients With Myelofibrosis and Anemia
On September 15, the U.S. Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post–polycythemia vera and post–essential thrombocythemia), in adults with anemia....
Decentralized Care Models Empower Equitable Pediatric Cancer Treatment
Childhood Cancer Awareness Month is recognized every September to help shine a light on the realities of pediatric cancer and raise awareness of the important work being done to make a difference for the children who are diagnosed with cancer. September 15 also marked the start of Hispanic Heritage ...
Comparing Radiation Therapies for NSCLC
Intensity-modulated radiation therapy may be the preferred treatment option for patients with locally advanced non–small cell lung cancer (NSCLC), according to findings presented by Chun et al at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer ...
AACR Issues Annual Cancer Progress Report
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)—over the past 3 decades, coupled with advances in cancer prevention and early detection, has led to a 33% reduction in cancer...
Decentralized Care Models Empower Equitable Pediatric Cancer Treatment
Childhood Cancer Awareness Month is recognized every September to help shine a light on the realities of pediatric cancer and raise awareness of the important work being done to make a difference for the children who are diagnosed with cancer. September 15 also marked the start of Hispanic Heritage ...
Expert Point of View: Priyanka Bhateja, MD
Head and neck cancer specialist Priyanka Bhateja, MD, Assistant Professor in the Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, was encouraged by the findings of the Quarterback trial. As she noted in her comments for The ASCO Post, human papillomavirus...
First-in-Class Bifunctional Antibody Plus Pembrolizumab Shows Activity in Head and Neck Squamous Cell Carcinoma
The first-in-class bifunctional antibody BCA101—which inhibits both the epidermal growth factor receptor (EGFR) and transforming growth factor-beta (TGF-β)—given with the immune checkpoint inhibitor pembrolizumab, is showing activity and tolerability in recurrent or metastatic head and neck...
Taiwanese Program Shows Potential for Detecting Early-Stage Lung Cancer
Researchers have found that the Taiwan National Lung Cancer Early Detection Program successfully detected 85% of stage 0 and stage I lung cancer cases. The findings by Yang et al were presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung...
Modified Classification of Pulmonary Adenocarcinomas May Be More Accurate Than WHO Classification System
A modified adenocarcinoma classification approach may enhance reproducibility and may be an improvement on the existing World Health Organization (WHO) classification system, according to findings presented by Thunnissen et al at the International Association for the Study of Lung Cancer (IASLC)...
ASCO Updates Guideline on Assessment, Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy
ASCO has updated a guideline on the practical assessment and management of age-associated vulnerabilities in older patients receiving systemic cancer therapy.1 Among the updates, the guideline adds more detail to domains that should be evaluated in geriatric assessments (GAs) and expands patient...
First-in-Class Bifunctional Antibody Plus Pembrolizumab Shows Activity in Head and Neck Squamous Cell Carcinoma
The first-in-class bifunctional antibody BCA101—which inhibits both the epidermal growth factor receptor (EGFR) and transforming growth factor-beta (TGF-β)—given with the immune checkpoint inhibitor pembrolizumab, is showing activity and tolerability in recurrent or metastatic head and neck...
More on Treatments Under Study in NSCLC From ASCO 2023
Two phase III trials presented at the 2023 ASCO Annual Meeting explored treatments under study for patients with non–small cell lung cancer (NSCLC). In an exploratory analysis of the CodeBreaK 200 trial, the KRAS inhibitor sotorasib was compared with docetaxel chemotherapy in subsets of patients...
More on Multiple Myeloma From ASCO 2023: Focus on Bispecific Antibodies
Two new bispecific antibodies—teclistamab and talquetamab—have been shown to be active in relapsed or refractory multiple myeloma when used in combination, including in patients with extramedullary disease, without compounding toxicity. Results of two clinical trials with these two agents were...
Predicting Recurrence in Colorectal Cancer Using Postoperative Circulating Tumor DNA Dynamics
Postoperative molecular residual disease detected by circulating tumor DNA (ctDNA) at 4 weeks after resection has emerged as the strongest prognostic risk factor for disease-free survival in patients with resected colorectal cancer. This finding was observed regardless of BRAF V600E status and...
Rising After Struggle: Surviving My First ASCO Breakthrough in Japan
After a year of hard work preparing a strong abstract for the prestigious 2023 ASCO Annual Meeting, I finally received an acceptance letter from the scientific committee. I was overjoyed to see the efforts of our multinational team being rewarded. A few moments later, I received the decision...
A Near-Future Look at Medicine When AI Has a Mind of Its Own
“Dr. Hope Kestrel was the only person who knew the patient in Room 132 wasn’t responding to the algorithm-selected treatment. She shuffled forward in the hospital security line, wanting to ger her day started already yet dreading how she’d tell her patient the unexpected and devastating news.” So...
Vitamin C and D Supplements for Patients With AML Undergoing Intensive Chemotherapy
Patients with acute myeloid leukemia (AML) who received vitamin C and D supplements during intensive chemotherapy had lower rates of complications such as infections, bleeding, and inflammation compared with patients who did not receive the supplements, according to a recent study published by...
Aaron C. Tan, PhD, MBBS, on Circulating Tumor DNA: Early Biomarker of Therapeutic Response in Phase I Trials
Aaron C. Tan, PhD, MBBS, of the National Cancer Centre Singapore, discusses new findings on early evaluation of circulating tumor DNA via low-pass whole-genome sequencing. The results of his study suggest this method may represent an early pharmacodynamic biomarker of therapeutic response...
Enhanced Recovery Program May Be Effective at Reducing Opioid Use After Pancreatic Cancer Surgery
Improving hospital care pathways may help reduce inpatient opioid use by 50% and cut the median opioid prescription volumes at discharge to zero in patients undergoing pancreatic cancer surgery, according to a recent study published by Boyev et al in JAMA Surgery. The new findings could help reduce ...
Can AI Assessment of Screening Mammograms Offer Similar Accuracy to Human Readers?
A commercially available artificial intelligence (AI) algorithm may perform comparably to human readers at assessing screening mammograms, according to a recent study published by Chen et al in Radiology. False-positive interpretations on screening mammograms can result in women without cancer...
Examining Disparities in Endometrial Cancer Outcomes Among Black Patients
Black patients with stage IA low-grade endometrioid endometrial carcinoma may be less likely to undergo a hysterectomy and survive their cancer than White patients with the same type of cancer, according to a recent study published by Taylor et al in Gynecologic Oncology. Background “We’ve known...
Improving Nutrition Guidance May Optimize Fertility Treatments for Female Cancer Survivors
Researchers have identified potential strategies to promote healthy dietary habits in female cancer survivors with fertility challenges, according to a recent study published by Klobodu et al in Integrative Cancer Therapies. Background Cancer may increase the risk of infertility in young female...
Divarasib in Patients With Advanced Solid Tumors and a KRAS G12C Mutation
In a phase I study reported in The New England Journal of Medicine, Sacher et al found that the covalent KRAS G12C inhibitor divarasib (also referred to as GDC-6036) produced durable responses in patients with advanced or metastatic solid tumors with a KRAS G12C mutation. In the study, 137 patients ...
Role of HER2 Expression in Hormone Receptor–Positive Metastatic Breast Cancer
This is Part 2 of Novel Therapies for Advanced Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Aditya Bardia, Sara Tolaney, and Antonio C. Wolff discuss the role of HER2 expression in hormone receptor–positive...
FDA Approves Luspatercept-aamt as First-Line Treatment for Adult Patients With Lower-Risk MDS and Anemia Who May Require Transfusions
On August 28, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) to treat anemia in adult patients with very low– to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell transfusions and who have not received previous...
Rural Patients With Cancer: Receipt of Surgical Care at High- vs Low-Volume Hospitals
Patients with cancer who live in rural Pennsylvania counties appear to know that they may have better outcomes if they receive their cancer surgery at a hospital that performs a high volume of those procedures—but many still opt for lower-volume hospitals closer to home when their cancer is likely...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Novel Targeted Therapy Combination May Be an Effective First-Line Option for Gastric or Gastroesophageal Junction Adenocarcinoma
Researchers have found that the novel targeted therapy zolbetuximab in combination with a standard chemotherapy may extend survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and overexpression of the claudin-18 isoform 2 protein (CLDN18.2), according to a novel...
Liquid Biopsy Assay Demonstrated Effectiveness in Early Cancer Detection in Asymptomatic Individuals in Vietnam
A Vietnamese prospective study by Hanh Thi-Hue Nguyen, BS, and Le Son Tran, PhD, both of the Medical Genetics Institute and Gene Solutions, Ho Chi Minh City, Vietnam, and colleagues, investigating the feasibility and performance of a circulating tumor DNA (ctDNA) analyzing test in the early...
New Challenge in Triple-Negative Breast Cancer: Optimizing the Sequencing of Treatments
New approaches are offering hope for better outcomes in metastatic triple-negative breast cancer, according to Suchita Pakkala, MD, of Emory University’s Winship Cancer Institute, Atlanta. She shared her thoughts on using PARP inhibitors and antibody-drug conjugates at the 2023 Debates and...
